tiprankstipranks
Trending News
More News >
CytoMed Therapeutics Limited (GDTC)
:GDTC
US Market
Advertisement

CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

Compare
10 Followers

Top Page

GDTC

CytoMed Therapeutics Limited

(NASDAQ:GDTC)

Rating:41Neutral
Price Target:
CytoMed Therapeutics Limited is facing significant financial challenges, with substantial declines in revenue and persistent losses. The technical indicators suggest a bearish trend with potential short-term opportunities due to oversold conditions. Valuation metrics, including a negative P/E ratio, reflect poor profitability and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for improved financial strategies and market conditions to enhance investor confidence.

CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company DescriptionCytoMed Therapeutics Limited (GDTC) is a biotechnology company focused on the development and commercialization of innovative cell-based therapies for the treatment of various diseases. The company is engaged in research and development activities primarily in the field of regenerative medicine, using advanced cellular technologies to address unmet medical needs. CytoMed's core products include a pipeline of therapeutic candidates designed to harness the power of cellular therapy to restore health and improve patient outcomes.
How the Company Makes MoneyCytoMed Therapeutics Limited generates revenue through the development and commercialization of its cell therapy products. The company invests in research and development to advance its pipeline of therapeutic candidates, which, once approved, are marketed and sold to healthcare providers and institutions. Revenue streams include product sales, potential licensing agreements, and strategic partnerships with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties. The company's financial success is contingent upon the successful approval and commercialization of its therapeutic candidates, as well as the establishment of collaborations with industry partners to enhance market reach and adoption.

CytoMed Therapeutics Limited Financial Statement Overview

Summary
Overall, CytoMed Therapeutics Limited faces significant financial hurdles, characterized by declining revenues, persistent losses, and cash flow deficits. Despite maintaining a strong equity position relative to debt, the company needs to address its cash management and revenue generation strategies to improve its financial health and stability.
Income Statement
30
Negative
The income statement reveals significant challenges, with the company experiencing a decline in total revenue from $290,560 in 2023 to $52,005 in 2024, indicating a negative revenue growth rate. Additionally, the net income remained negative, with a considerable net loss of $1,883,178 in 2024, reflecting poor profitability and a concerning net profit margin.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, resulting in a low debt-to-equity ratio. However, the reduction in total assets and stockholders' equity from 2023 to 2024 highlights potential risks and financial instability.
Cash Flow
35
Negative
The cash flow statement indicates negative operating cash flow, with a substantial free cash flow deficit of $2,742,350 in 2024. While the company had a significant capital expenditure in 2024, the free cash flow remains negative, pointing to cash management challenges and the need for more efficient cash utilization.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue52.01K290.56K
Gross Profit-515.82K213.09K
EBITDA-1.79M-2.94M
Net Income-1.88M-3.13M
Balance Sheet
Total Assets7.38M12.37M
Cash, Cash Equivalents and Short-Term Investments3.64M9.00M
Total Debt463.25K448.02K
Total Liabilities750.59K1.12M
Stockholders Equity6.57M8.49M
Cash Flow
Free Cash Flow-2.74M
Operating Cash Flow-1.69M-2.60M
Investing Cash Flow494.59K
Financing Cash Flow-33.36K8.27M

CytoMed Therapeutics Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.88
Price Trends
50DMA
2.13
Negative
100DMA
2.26
Negative
200DMA
2.42
Negative
Market Momentum
MACD
-0.09
Positive
RSI
33.90
Neutral
STOCH
25.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 1.88 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.13, and below the 200-day MA of 2.42, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 33.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.

CytoMed Therapeutics Limited Risk Analysis

CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CytoMed Therapeutics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$56.48M-45.40%4413.19%10.56%
51
Neutral
$7.37B0.33-68.87%2.37%16.45%0.47%
50
Neutral
$31.35M-1738.36%-43.55%69.81%
41
Neutral
$22.97M-24.97%38.80%
41
Neutral
$34.75M-853.05%34.97%
40
Underperform
$5.88M-66.15%43.03%81.75%
39
Underperform
$30.61M-282.07%-220.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GDTC
CytoMed Therapeutics Limited
1.83
0.29
18.83%
TPST
Tempest Therapeutics
7.49
-10.58
-58.55%
VYNE
VYNE Therapeutics
0.35
-1.42
-80.23%
CLNN
Clene
3.49
-0.51
-12.75%
PYPD
PolyPid
3.41
-0.11
-3.12%
BRNS
Barinthus Biotherapeutics
1.40
0.01
0.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025